These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 16061861)

  • 1. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers.
    Krajewska M; Kim H; Kim C; Kang H; Welsh K; Matsuzawa S; Tsukamoto M; Thomas RG; Assa-Munt N; Piao Z; Suzuki K; Perucho M; Krajewski S; Reed JC
    Clin Cancer Res; 2005 Aug; 11(15):5451-61. PubMed ID: 16061861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
    Zlobec I; Baker K; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
    Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
    Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products.
    Langlois NE; Lamb J; Eremin O; Heys SD
    J Pathol; 1997 Aug; 182(4):392-7. PubMed ID: 9306959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
    Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
    Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.
    Kawasaki H; Altieri DC; Lu CD; Toyoda M; Tenjo T; Tanigawa N
    Cancer Res; 1998 Nov; 58(22):5071-4. PubMed ID: 9823313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
    Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
    Paradiso A; Simone G; Lena MD; Leone B; Vallejo C; Lacava J; Dellapasqua S; Daidone MG; Costa A
    Br J Cancer; 2001 Mar; 84(5):651-8. PubMed ID: 11237386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
    Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
    Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
    J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer.
    Wright CM; Dent OF; Barker M; Newland RC; Chapuis PH; Bokey EL; Young JP; Leggett BA; Jass JR; Macdonald GA
    Br J Surg; 2000 Sep; 87(9):1197-202. PubMed ID: 10971428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells.
    Lloyd JM; McIver CM; Stephenson SA; Hewett PJ; Rieger N; Hardingham JE
    Clin Cancer Res; 2006 Jan; 12(2):417-23. PubMed ID: 16428481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.